Growing Dicerna moves into Cambridge supercluster

Dicerna CEO Douglas Fambrough

Now that Dicerna has cashed in on the biotech IPO gold rush, the biotech ($DRNA) has moved closer to where the action is. Local VIPs are gathering this morning to cut the ribbon on the biotech's new 37,000-square-foot office and R&D center in Cambridge. The 2010 Fierce 15 company--which moved in from nearby Watertown--has been raking in cash while enjoying some rising expectations for RNAi. "Dicerna has more than doubled its footprint in the new space and now employs approximately 45 people, with plans to hire an additional 10 employees this year, and many more going forward," says Dicerna CEO Douglas Fambrough. Release

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.